Blog

Ciara C. O’Sullivan of Mayo Clinic, leads the Alliance A011801 trial – Alliance for Clinical Trials in Oncology

Photo from Alliance for Clinical Trials in Oncology/LinkedIn

May 17, 2024, 13:16

Ciara C. O’Sullivan of Mayo Clinic, leads the Alliance A011801 trial – Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology shared on LinkedIn:

“For Trial Tuesday, Ciara C. O’Sullivan, MB, BCh, of Mayo Clinic, leads the Alliance A011801 (CompassHER2 RD) trial to see how targeted therapy linked to a chemotherapy drug works to prevent breast cancer from returning in patients with high-risk HER2+ breast cancer. To learn more about the CompassHER2 RD trial.”

Further Reading.
Source: Alliance for Clinical Trials in Oncology/LinkedIn

Alliance A011801 Alliance for Clinical Trials in Oncology cancer chemotherapy Ciara C. O'Sullivan CompassHER2 RD trial HER2+ breast cancer Mayo Clinic OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage